Patents Assigned to KMT Hepatech, Inc.
  • Animal model having a chimeric human liver and susceptible to human hepatitis C virus infection
    Patent number: 8445745
    Abstract: The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection. The animals of the invention are also useful in assessing toxicity of various agents, as well as the activity of agents in decreasing blood lipids.
    Type: Grant
    Filed: May 30, 2012
    Date of Patent: May 21, 2013
    Assignee: KMT Hepatech, Inc.
    Inventors: Norman M. Kneteman, D. Lorne Tyrrell, David Frederick Mercer
  • Animal model having a chimeric human liver and susceptible to human hepatitis C virus infection
    Patent number: 8212106
    Abstract: The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection. The animals of the invention are also useful in assessing toxicity of various agents, as well as the activity of agents in decreasing blood lipids.
    Type: Grant
    Filed: July 20, 2010
    Date of Patent: July 3, 2012
    Assignee: KMT Hepatech, Inc.
    Inventors: Norman M. Kneteman, D. Lorne Tyrrell, David Frederick Mercer
  • Animal model having a chimeric human liver and susceptible to human hepatitis C virus infection
    Patent number: 7781642
    Abstract: The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection. The animals of the invention are also useful in assessing toxicity of various agents, as well as the activity of agents in decreasing blood lipids.
    Type: Grant
    Filed: December 11, 2008
    Date of Patent: August 24, 2010
    Assignee: KMT Hepatech, Inc.
    Inventors: Norman M. Kneteman, D. Lorne Tyrrell, David Frederick Mercer
  • Animal model having a chimeric human liver
    Patent number: 7498479
    Abstract: The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection. The animals of the invention are also useful in assessing toxicity of various agents, as well as the activity of agents in decreasing blood lipids.
    Type: Grant
    Filed: September 7, 2006
    Date of Patent: March 3, 2009
    Assignee: KMT Hepatech, Inc.
    Inventors: Norman M. Kneteman, D. Lorne Tyrrell, David F. Mercer
  • Malarial animal model having a chimeric human liver
    Patent number: 7273963
    Abstract: The present invention features a non-human animal model of malaria, e.g., Plasmodium, particularly Plasmodium falciparum. The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having anti-pathogenic activity against malaria.
    Type: Grant
    Filed: August 17, 2005
    Date of Patent: September 25, 2007
    Assignees: KMT Hepatech, Inc., University of Maryland, Baltimore
    Inventors: Norman M. Kneteman, John B. Sacci, Jr., D. Lorne Tyrrell, John F. Elliott, Abdu F. Azad
  • Animal model having a chimeric human liver
    Patent number: 7161057
    Abstract: The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection. The animals of the invention are also useful in assessing toxicity of various agents, as well as the activity of agents in decreasing blood lipids.
    Type: Grant
    Filed: September 12, 2002
    Date of Patent: January 9, 2007
    Assignee: KMT Hepatech, Inc.
    Inventors: Norman M. Kneteman, D. Lorne Tyrrell, David F. Mercer
  • Chimeric animal model susceptible to human hepatitis C virus infection
    Patent number: 6509514
    Abstract: The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised xenogeneic transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection.
    Type: Grant
    Filed: March 17, 2000
    Date of Patent: January 21, 2003
    Assignee: KMT Hepatech, Inc.
    Inventors: Norman M. Kneteman, D. Lorne Tyrrell, David F. Mercer